A long-term study of symptoms, spirometry and survival amongst home nebulizer users

Respiratory Medicine

Volumn 90, Issue 9, 1996, Pages 561-566

  O'Driscoll, B R ^a   Bernstein, A ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; SALBUTAMOL;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; FEMALE; FORCED EXPIRATORY VOLUME; HOME CARE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG CANCER; LUNG FUNCTION TEST; MALE; NEBULIZER; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY FAILURE; SPIROMETRY; SURVIVAL RATE; SYMPTOMATOLOGY; TACHYPHYLAXIS; TIME;

EID: 0029839102     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90149-3     Document Type: Article

References (18)

1. Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulised salbutamol and salbutamol from a metered dose inhaler in stable chronic airflow limitation. Chest 1987; 91: 804-807.
2. O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MCP, Bernstein A. A long-term prospective assessment of home nebuliser treatment. Respir Med 1992; 86: 317-325.
3. Morrison JFJ, Jones PC, Muers MF. Assessing physiological benefit from domiciliary nebulised bronchodilators in severe airflow limitation. Eur Respir J 1992; 5: 424-429.
4. Mestitz H, Copland JM, McDonald CF. Comparison of outpatient nebulised VS metered dose inhaler terbutaline in chronic airflow obstruction. Chest 1898; 96: 1237-1240.
5. Boe J. Domiciliary nebulised beta agonists. Eur J Respir Dis 1984; 65 (Suppl. 136): 193-202.
6. 2 stimulants - a retrospective follow up of 102 patients. Eur J Respir Dis 1984; 65 (Suppl. 136): 205-213.
7. Burrows B, Lebowitz MD. The beta-agonist dilemma. N Engl J Med 1992; 326: 560-561.
8. Sears MR, Rea HH, Fenwick J et al. 75 deaths in asthmatics prescribed home nebulisers. BMJ 1987; 294: 477-480.
9. British Thoracic Society Guidelines on the Use of Nebulised Treatment. Thorax 1996 (in press).
10. Cooper CB. Life expectancy in severe COPD. Chest 1994; 35: 335-336.
11. Mullen ML, Mullen B, Carey M. The association between beta-agonist use and death from asthma. JAMA 1993; 270: 1842-1845.
12. Davis C, Connolly ME. Tachyphylaxis to beta agonists in human bronchial smooth muscle in vitro. Br J Clin Pharmac 1990; 10: 417-423.
13. 2-agonists and asthma. BMJ 1991; 302: 1166-1167.
14. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
15. Spitzer WO, Suissa S, Ernst P et al. The use of beta agonists and the risk of death or near death from asthma. N Engl J Med 1992; 326: 501-506.
16. Burrows B, Bloom JW, Traver GA, Cline MS. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Eng J Med 1987; 317: 1309-1314.
17. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease: A prospective study of 200 patients. N Eng J Med 1969; 280: 397-404.
18. Campbell AH, Barter CE, O'Connell JM, Huggins R. Factors affecting the decline of ventrilatory function in chronic bronchitis. Thorax 1985; 40: 741-748.